Rick, V1, Peter,
I see Rastetter's letter as making two major points, one valid the other not so. This letter is in reply to a piece on Coulter that may have presented Bexxar as better or the same as Rituxan. I never saw the IBD Coulter piece, just heard it mentioned in the threads.
As of December of 1997, one has to agree with CEO R. that Rituxan is a drug while Bexxar is an experimental compound (this may change in a year or two, but we are not there yet). This, I think, is his valid point. Then he goes on to argue that Bexxar and Y2B8 may be seen as equivalent, and this is not so valid, for similar reasons; Bexxar is due to complete, what appear as successful, trials that will support registration well within the next 12 months; Y2B8 is nowhere near that. V1 has also reminded us that Y2B8 may have less favorable therapeutic features than Bexxar.
PB
P.S. Rick did you get maxoide's e-mail? |
